Compare Abeona Therapeutics Inc (ABEO) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Meta Platforms Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Meta Platforms Inc trades at $603 (market cap $1.56T). The key difference: Meta Platforms Inc is far larger — about 4178.7× Abeona Therapeutics Inc's market cap, and Meta Platforms Inc pays a 0.34% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | META | |
|---|---|---|
Market Cap | $373.32M | $1.56T |
Sector | Health | Media |
52-Week High | $7.23 | $790.00 |
52-Week Low | $4.17 | $525.72 |
Enterprise Value | $228.22M | $1.57T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
META trades at $603.03, up 0.46% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $7.31 exceeding the $6.70 estimate. Revenue grew to $201.0B in 2025, and profitability remains robust with a net margin of 32.84%. Recent news highlights the launch of the Muse Spark AI model, driving positive sentiment.
The outlook is positive given analyst consensus with a $826.50 price target and 79% buy ratings. Key opportunities include AI monetization and revenue growth, while risks involve regulatory lawsuits and high capital expenditure. The stock offers upside potential but faces execution and legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
